Fundamental Analysis of NEWAMSTERDAM PHARMA CO NV(NASDAQ:NAMS) stock

Fundamental Rating

Overall NAMS gets a fundamental rating of 2 out of 10. We evaluated NAMS against 573 industry peers in the Biotechnology industry. The financial health of NAMS is average, but there are quite some concerns on its profitability. NAMS has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year NAMS has reported negative net income.

1.2 Ratios

NAMS has a better Return On Assets (-16.57%) than 82.92% of its industry peers.

NAMS has a Return On Equity of -18.48%. This is amongst the best in the industry. NAMS outperforms 87.50% of its industry peers.

		Industry Rank	Sector Rank
ROA	-16.57%
ROE	-18.48%
ROIC	N/A

ROA(3y)-3.89%

ROA(5y)N/A

ROE(3y)-4.3%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

NAMS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

NAMS does not have a ROIC to compare to the WACC, probably because it is not profitable.

NAMS has more shares outstanding than it did 1 year ago.

NAMS has a worse debt/assets ratio than last year.

2.2 Solvency

An Altman-Z score of 17.63 indicates that NAMS is not in any danger for bankruptcy at the moment.

With an excellent Altman-Z score value of 17.63, NAMS belongs to the best of the industry, outperforming 92.61% of the companies in the same industry.

NAMS has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.

With a Debt to Equity ratio value of 0.00, NAMS perfoms like the industry average, outperforming 51.94% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	17.63

ROIC/WACCN/A

WACC7.96%

2.3 Liquidity

NAMS has a Current Ratio of 10.15. This indicates that NAMS is financially healthy and has no problem in meeting its short term obligations.

NAMS's Current ratio of 10.15 is amongst the best of the industry. NAMS outperforms 80.63% of its industry peers.

A Quick Ratio of 10.15 indicates that NAMS has no problem at all paying its short term obligations.

The Quick ratio of NAMS (10.15) is better than 80.63% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	10.15
Quick Ratio	10.15

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

NAMS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -505.51%.

EPS 1Y (TTM)-505.51%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-1283.85%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

NAMS is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -49.87% yearly.

Based on estimates for the next years, NAMS will show a small growth in Revenue. The Revenue will grow by 3.29% on average per year.

EPS Next Y-1136.93%

EPS Next 2Y-159.31%

EPS Next 3Y-105.59%

EPS Next 5Y-49.87%

Revenue Next Year-93.22%

Revenue Next 2Y-23.12%

Revenue Next 3Y-62.42%

Revenue Next 5Y3.29%

3.3 Evolution

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

NAMS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year NAMS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A cheap valuation may be justified as NAMS's earnings are expected to decrease with -105.59% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-159.31%

EPS Next 3Y-105.59%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for NAMS!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

NEWAMSTERDAM PHARMA CO NV

NASDAQ:NAMS (9/18/2024, 4:30:02 PM)

After market: 15.95 0 (0%)

15.95

+0.5 (+3.24%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap1.44B

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-16.57%
ROE	-18.48%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.21

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	10.15
Quick Ratio	10.15
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)-505.51%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y-1136.93%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

NEWAMSTERDAM PHARMA CO NV (NAMS)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens